Future Of Medicines Pricing And Supply Will Be ‘Radically Different’, IPHA Tells NCPE Conference

  • Pace of pharmaceutical innovation means change in the reimbursement model is inevitable
  • Funding for new medicines will be greater than the opportunity to save on older medicines
  • Medicines spending must be considered an ‘investment in outcomes’

Read more

Ireland Can Be A European Leader In Clinical Trials, IPHA Tells HRB-CRCI Conference

Ahead of International Clinical Trials Day, pharmaceutical innovators call for:

  • The standardisation of site contracts (the Clinical Trial Agreement), in place in most other EU countries
  • Protected research time for clinicians and hospital staff
  • Realistic targets for clinical trials that are achievable and can be relied upon
  • Partnership approach between clinicians, policymakers, patients and industry to eliminate delays recruiting patients

Read more

Intellectual property must be safeguarded to ensure ongoing breakthroughs in innovative medicines

On World IP Day, pharmaceutical innovators say it’s vital that the intellectual property (IP) rights that enhance the development of innovative medicines in Europe are protected and not further eroded.

Read more

Pharmaceutical Industry Must Be Part of New Government Alliance to Boost Vaccination Rates

On World Immunisation Week, pharmaceutical innovators say it’s vital to take steps to reduce vaccine hesitancy and to dispel ‘damaging’ myths about vaccination.

Read more

New Europe-wide Data Shows New Medicines Face Growing Delays Reaching Irish Patients

New data shows Irish patients face growing delays accessing new medicines, ranking well into the bottom half of European countries surveyed as part of a comprehensive analysis of wait times and rates of availability.

Read more

IPHA Presses to Place Innovation at the Heart of Europe as Elections Draw Near

As the campaign begins ahead of the European Parliament elections on May 24th, the Irish Pharmaceutical Healthcare Association (IPHA) has called on candidates to back progress in biopharmaceutical innovation as the basis for new jobs, investments and therapies in Ireland.

 

Read more

New Medicines Waited Almost 2.5 Years For Reimbursement Decisions, says IPHA

 

 

New figures show 10 innovative treatments approved by the HSE for use by patients spent 890 days awaiting decisions.

The 10 new innovative medicines recently approved by the Health Service Executive for use by patients spent on average almost two-and-a-half years waiting for a reimbursement decision, according to the Irish Pharmaceutical Healthcare Association (IPHA), the body representing the research-based pharmaceutical industry.

Read more